Buoyed by Dupixent, Sanofi expects a brighter 2019 by Angus Liu Thursday, February 7, 2019 After a strong fourth quarter, Sanofi expects further growth in 2019.
Dupixent and vaccines bring Sanofi back to growth by Angus Liu Wednesday, October 31, 2018 Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.
Sanofi teams with ALA on flu-shot message to U.S. seniors by Eric Sagonowsky Monday, October 15, 2018 As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.
Cell-derived flu strain provides a better match than eggs: study by Eric Sagonowsky Wednesday, October 10, 2018 Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.
Sanofi ships first of 70M doses of flu shots for the 2018-19 season by Angus Liu Tuesday, July 31, 2018 Sanofi will increase the supplies of Flublok Quadrivalent and Fluzone High-Dose to 25 million doses for the coming flu season.
3. Sanofi by Angus Liu By the numbers, Sanofi’s vaccines business did quite well in 2017. Revenue grew an impressive 8.3% to reach €5.1 billion ($6.12 billion). But beyond the income statement, last year wasn’t without headline-hogging controversies and setbacks.
Cell-based flu shots offer slight advantage for seniors: report by Angus Liu Wednesday, June 27, 2018 Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.
Sanofi hiked Flublok price 12.5% last season by Eric Sagonowsky Wednesday, June 6, 2018 Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.
Sanofi tweaks pricing policies, discloses 8.4% net price decline in 2017 by Eric Sagonowsky Friday, June 1, 2018 Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.
Sanofi licenses cell-based vaccine technology in $155M deal by Angus Liu Monday, February 12, 2018 The licensing deal provides Sanofi Pasteur access to a cell culture technology for use in its universal influenza vaccine.
